Cyclo Therapeutics, INC Form 4 insider transactions

Director Francis Patrick Ostronic reports acquisition of common stock and stock options in Cyclo Therapeutics in lieu of cash compensation.

Director C.E. Rick Strattan received shares and options from Cyclo Therapeutics on June 3, 2024, according to a Form 4 filing.

Randall M. Toig, a director of Cyclo Therapeutics, Inc., acquired shares and options as part of his compensation, according to a recent SEC filing.

Director Shawn Cross received 8,887 shares of common stock and options to purchase 15,562 shares of Cyclo Therapeutics, Inc. (CYTH) on June 3, 2024.

N. Scott Fine, CEO of Cyclo Therapeutics, Inc., reports the acquisition of stock options.

Director Vivien Wong reports acquisition of common stock in lieu of cash compensation and grant of stock options.

Director William Conkling reports acquisition of common stock in lieu of cash compensation and grant of stock options in Cyclo Therapeutics.